Current concerns and difficulties in the prevention of cardiovascular diseases

Hellenic Journal of Cardiology

Volumn 52, Issue 5, 2011, Pages 437-441

  Rallidis, Loukianos S ^a   Anastasiou Nana, Maria I ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cardiovascular disease prevention; Hygienic dietary interventions; Residual cardiovascular risk

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTICLE; ATHEROGENESIS; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY CALCIUM SCORE; CORONARY ARTERY DISEASE; DIET THERAPY; DYSLIPIDEMIA; EXERCISE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; MONOTHERAPY; PREVENTION STUDY; PROCAM SCORE; REYNOLDS RISK SCORE; SCORING SYSTEM; SMOKING CESSATION; WEIGHT REDUCTION;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; MODELS, STATISTICAL; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 80053101734     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-1278.
2. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352: 1425-1435.
3. Fruchart J-C, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008; 102: 1K-34K.
4. Ginsberg HN, Elam MB, Lovato LC, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1563-1574.
5. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010; 55: 1310-1317.
6. Dent THS. Predicting the risk of coronary heart disease I. The use of conventional risk markers. Atherosclerosis. 2010; 213: 345-351.
7. Pipilis A, Kaliambakos S, Xenodochidis C, Tsakonas G, Sourlas N, Mallios K. Overestimation and underestimation of cardiovascular risk in clinical practice: usefulness of risk estimation charts. Hellenic J Cardiol. 2007; 48: 341-345.
8. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 151: 483-495.
9. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195-2207.
10. Thompson A, Gao P, Orfei L, et al; Lp-PLA(2) Studies Collaboration. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010; 375: 1536-1544.
11. Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010; 303: 1610-1616.
12. Shah PK. Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we? J Am Coll Cardiol. 2010; 56: 98-105.
13. Stefanadis CI. Evaluation of cardiovascular risk in the asymptomatic patient: beyond the classical risk factors and towards vascular age. Hellenic J Cardiol. 2009; 50: 87-88.
14. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008; 21: 93-111.
15. de Groot E, van Leuven SI, Duivenvoorden R, et al. Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis. Nat Clin Pract Cardiovasc Med. 2008; 5: 280-288.
16. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J. 1997; 18: 1569-1582.
17. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001; 22: 554-572.
18. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009; 373: 929-940.
19. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239.
20. Rallidis LS, Lekakis J, Kremastinos DT. Current questions regarding the use of statins in patients with coronary heart disease. Int J Cardiol. 2007; 122: 188-194.
21. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005; 96: 556-563.
22. Elisaf MS, Nikas N. Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs-the CEPHEUS-Greece survey. Angiology. 2010; 61: 465-474.
23. Rallidis LS, Kotakos C, Sourides V, et al. Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: a 3 year follow-up. Expert Opin Pharmacother. 2011; 12: 1481-1489.
24. Vardas PE. Implementation of ESC guidelines: is it primarily a scientific, political, or financial matter? Hellenic J Cardiol. 2010; 51: 193-194.
25. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007; 116: e148-304.